Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365551 | 0.87 | MGAM (0.58) | MGAMBACE1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13791878 | 0.84 | BACE1 (0.50) | MGAMBACE1ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL262639 | 0.84 | BACE1 (0.50) | BACE1ALDH1A1SMN1; SMN2HTTHDAC1 | |
| SCHEMBL16093684 | 0.84 | BACE1 (0.55) | BACE1ALDH1A1KDM4ESMN1; SMN2HDAC1 | |
| Hydrochloric Acid SCHEMBL3880519 | 0.82 | BACE1 (0.49) | MGAMBACE1ALDH1A1SMN1; SMN2HDAC1 | |
| SCHEMBL1128619 | 0.82 | CNR2 (0.66) | MGAMBACE1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1293647 | 0.81 | BACE1 (0.47) | MGAMBACE1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL12405037 | 0.80 | MGAM (0.63) | MGAMALDH1A1KDM4ESMN1; SMN2ALOX15 | |
| SCHEMBL2004085 | 0.80 | ABCG2 (0.55) | BACE1ALDH1A1KDM4ESMN1; SMN2HTT | |
| SCHEMBL2723291 | 0.80 | BACE1 (0.46) | BACE1ALDH1A1SMN1; SMN2HTTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115947720-B | Design, preparation and application of beta 3 adrenergic receptor anchoring probe | 南京师范大学 | 2024-03-29 | — | — | CN | claimed |
| CN-115947720-A | Design of beta 3 adrenergic receptor anchoring probe and preparation method and application thereof | 南京师范大学 | 2023-04-11 | — | — | CN | claimed |
| CN-114426534-B | Reversible fluorescent probe for detecting copper ions and preparation method thereof | 南京师范大学 | 2023-01-31 | — | — | CN | claimed |
| CN-114426534-A | Reversible fluorescent probe for detecting copper ions and preparation method thereof | 南京师范大学 | 2022-05-03 | — | — | CN | claimed |
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119325469-A | WEE1 degrading compounds and uses thereof | 百时美施贵宝公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-115947720-B | Design, preparation and application of beta 3 adrenergic receptor anchoring probe | 南京师范大学 | 2024-03-29 | — | — | CN | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023231948-A1 | ISR INHIBITORS, METHOD FOR PREPARING SAME, AND USE THEREOF | 中国药科大学 | 2023-12-07 | — | — | WO | disclosed |
| CN-116874468-A | Synthesis and application of small molecular compound with 2-pyridine substituted formamide structure | 江西中医药大学 | 2023-10-13 | — | — | CN | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MGAM 2908/4885BACE1 1242/4885ALDH1A1 3253/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | MGAM 370/4885BACE1 249/4885ALDH1A1 3361/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | MGAM 138/4885BACE1 544/4885ALDH1A1 3232/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | MGAM 1320/4885BACE1 2266/4885ALDH1A1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.